Position in AKTS
as of Jun 30, 2026
· filed Jul 22, 2026
Position Value
$1,063
New position
Shares Held
33
first reported quarter
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#8
of 10 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 0%
Shared 0%
None 100%
Position in Biotechnology
Healthcare · as of Jun 30, 2026SJS Investment Consulting Inc. holds $1,411,656 across 170 Biotechnology names. AKTS ranks #78 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | SLS |
SELLAS Life Sciences Group, Inc.
|
40,000 | $590,400 | |
| 2 | JAZZ |
Jazz Pharmaceuticals plc
|
840 | $202,414 | |
| 3 | TNXP |
Tonix Pharmaceuticals Holding Corp.
|
10,204 | $130,203 | |
| 4 | BMRN |
Biomarin Pharmaceutical Inc
|
877 | $50,181 | |
| 5 | EXEL |
Exelixis, Inc.
|
821 | $44,670 | |
| 6 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
59 | $29,306 | |
| 7 | REGN |
Regeneron Pharmaceuticals, Inc.
|
47 | $29,305 | |
| 8 | INCY |
Incyte Corp
|
208 | $23,578 |
All Filings in AKTS
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,063 | 33 | Shares | Defined | 2026-07-22 | |
| No filing history on record for this holder in this stock. | ||||||